+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H1 2020

  • ID: 5117079
  • Drug Pipelines
  • May 2020
  • Region: Global
  • 1536 pages
  • Global Markets Direct

FEATURED COMPANIES

  • 4SC AG
  • CanBas Co Ltd
  • Fate Therapeutics Inc
  • Incyte Corp
  • NantKwest Inc
  • Retrotherapy LLC
  • MORE
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H1 2020

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Acute Lymphocytic Leukemia – Pipeline Review, H1 2020, provides an overview of the Acute Lymphocytic Leukemia (Oncology) pipeline landscape.

Acute lymphocytic leukemia (ALL) is the cancer of the white blood cells due to the production of a large number of immature lymphocytes thus blocking the production of normal blood cells. It enters the blood stream and rapidly progress to other parts of the body such as spleen, lymph nodes and liver. Risk factors for ALL include exposure to radiation or chemicals, age, virus infections and genetic factors. Symptoms include anemia, frequent infections, easy bruising, bone pain and breathing problems. Treatment includes chemotherapy, transfusions, transplant and medications.

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Acute Lymphocytic Leukemia – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Acute Lymphocytic Leukemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acute Lymphocytic Leukemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 6, 86, 80, 7, 8, 86, 12 and 5 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages comprises 2, 34, 28, 28, 2 and 1 molecules, respectively.

Acute Lymphocytic Leukemia (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Lymphocytic Leukemia (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Acute Lymphocytic Leukemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Acute Lymphocytic Leukemia (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Acute Lymphocytic Leukemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Acute Lymphocytic Leukemia (Oncology)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Acute Lymphocytic Leukemia (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Acute Lymphocytic Leukemia (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • 4SC AG
  • CanBas Co Ltd
  • Fate Therapeutics Inc
  • Incyte Corp
  • NantKwest Inc
  • Retrotherapy LLC
  • MORE
  • Introduction
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Overview
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics Development
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics Assessment
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Companies Involved in Therapeutics Development
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Drug Profiles
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Dormant Projects
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Discontinued Products
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Product Development Milestones
  • Appendix
List of Tables
  • Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020 (Contd..2), H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020 (Contd..3), H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
  • Products under Development by Universities/Institutes, H1 2020 (Contd..2), H1 2020
  • Products under Development by Universities/Institutes, H1 2020 (Contd..3), H1 2020
  • Products under Development by Universities/Institutes, H1 2020 (Contd..4), H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..3), H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..4), H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..5), H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..6), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..3), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..4), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..5), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..6), H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by 4SC AG, H1 2020
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by AbbVie Inc, H1 2020
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Actinium Pharmaceuticals Inc, H1 2020
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by ADC Therapeutics SA, H1 2020
List of Figures
  • Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Top 10 Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020
Note: Product cover images may vary from those shown
  • 4SC AG
  • AbbVie Inc
  • Actinium Pharmaceuticals Inc
  • ADC Therapeutics SA
  • Adlai Nortye Biopharma Co Ltd
  • Aeglea BioTherapeutics Inc
  • Aileron Therapeutics Inc
  • AIMM Therapeutics BV
  • Aleta Biotherapeutics Inc
  • Allterum Therapeutics LLC
  • Amgen Inc
  • Angiocrine Bioscience Inc
  • Anhui Anke Biotechnology (Group) Co Ltd
  • Apexian Pharmaceuticals Inc
  • Applied Therapeutics Inc
  • AstraZeneca Plc
  • Atara Biotherapeutics Inc
  • AUM Biosciences Pte Ltd
  • Autolus Therapeutics Plc
  • Avalon GloboCare Corp
  • AVM Biotechnology LLC
  • Ayala Pharmaceuticals Inc
  • Beam Therapeutics Inc
  • Beijing Immunochina Medical Science & Technology Co Ltd
  • Bellicum Pharmaceuticals Inc
  • Bio-Cancer Treatment International Ltd
  • Bio-Path Holdings Inc
  • Bioceltech Therapeutics Ltd
  • Biocure Technology Inc
  • BioSight Ltd
  • Bristol-Myers Squibb Co
  • Cambridge Innovation Technologies Consulting Ltd
  • CanBas Co Ltd
  • CARsgen Therapeutics Ltd
  • CASI Pharmaceuticals Inc
  • Cellectis SA
  • Cellestia Biotech AG
  • Cellipse SAS
  • Cellular Biomedicine Group Inc
  • Celularity Inc
  • China Immunotech Co Ltd
  • CoImmune Inc
  • CRISPR Therapeutics AG
  • Cyclacel Pharmaceuticals Inc
  • Cyteir Therapeutics Inc
  • Daiichi Sankyo Co Ltd
  • Deciphera Pharmaceuticals Inc
  • Delta-Fly Pharma Inc
  • DevaCell Inc
  • Dialectic Therapeutics Inc
  • Diazon Pharmaceuticals Inc
  • DiNonA Inc
  • Elf Zone Inc
  • Eli Lilly and Co
  • Enzyme by Design Inc
  • Epizyme Inc
  • ERYTECH Pharma SA
  • Eureka Therapeutics Inc
  • ExCellThera Inc
  • F. Hoffmann-La Roche Ltd
  • Fate Therapeutics Inc
  • Felicitex Therapeutics Inc
  • Fusion Pharma LLC
  • Gamida Cell Ltd
  • Gansu Provincial Cancer Hospital
  • GEMoaB Monoclonals GmbH
  • Generium
  • Generon (Shanghai) Corp Ltd
  • Genexine Inc
  • Gilead Sciences Inc
  • Gracell Biotechnology Ltd
  • GT Biopharma Inc
  • Guangzhou Bio-gene Technology Co Ltd
  • Hangzhou Minsheng Pharmaceutical Group Co Ltd
  • Hebei Senlang Biotechnology Inc Ltd
  • HemoGenyx LLC
  • HighPass Bio Inc
  • Hillstream BioPharma Inc
  • Housey Pharmaceutical Research Laboratories LLC
  • HRAIN Biotechnology Co Ltd
  • Humanigen Inc
  • Hummingbird Bioscience Pte Ltd
  • Hunan Siweikang Therapeutics Ltd
  • iCell Gene Therapeutics LLC
  • iDD biotech SAS
  • Iksuda Therapeutics Ltd
  • ImCheck Therapeutics SAS
  • ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
  • ImmunityBio Inc
  • ImmunoGen Inc
  • Immunomedics Inc
  • Immunotech Biopharm Ltd
  • Inatherys
  • Incuron LLC
  • Incysus Therapeutics Inc
  • Incyte Corp
  • Innovative Cellular Therapeutics Co Ltd
  • Interprotein Corp
  • Jazz Pharmaceuticals Plc
  • Johnson & Johnson
  • Juno Therapeutics Inc
  • Juventas Cell Therapy Ltd
  • Karyopharm Therapeutics Inc
  • Kecellitics Biotech Co Ltd
  • Kiromic BioPharma Inc
  • Kronos Bio Inc
  • Kuur Therapeutics Ltd
  • LegoChem Biosciences Inc
  • Les Laboratoires Servier SAS
  • Light Chain Bioscience
  • Lin Bioscience Inc
  • MAA Laboratories Inc
  • MacroGenics Inc
  • Magenta Therapeutics Inc
  • MannKind Corp
  • Marker Therapeutics Inc
  • Medivir AB
  • Merck & Co Inc
  • Meryx Inc
  • Millennium Pharmaceuticals Inc
  • Miltenyi Biotec GmbH
  • Molecular Templates Inc
  • Nanjing Bioheng Biotech Co Ltd
  • Nanjing Iaso Biotherapeutics Co Ltd
  • Nanjing KAEDI Biotech Inc
  • Nanjing Legend Biotech Co Ltd
  • Nanovalent Pharmaceuticals Inc
  • NantKwest Inc
  • Nimbus Therapeutics LLC
  • Nkarta Inc
  • Nohla Therapeutics Inc
  • Novartis AG
  • NovoMedix LLC
  • Omeros Corp
  • Oncoceutics Inc
  • Onconova Therapeutics Inc
  • OncoTartis Inc
  • OncoTherapy Science Inc
  • Orca Biosystems Inc
  • OSE Immunotherapeutics
  • Pascal Biosciences Inc
  • PentixaPharm GmbH
  • PeproMene Bio Inc
  • PersonGen Biomedicine Suzhou Co Ltd
  • Pfenex Inc
  • Pfizer Inc
  • Pharma Mar SA
  • PharmaEssentia Corp
  • Precision Biosciences Inc
  • Protheragen Inc
  • PTC Therapeutics Inc
  • Regenacy Pharmaceuticals LLC
  • Regeneron Pharmaceuticals Inc
  • Retrotherapy LLC
  • Ryvu Therapeutics SA
  • Samus Therapeutics LLC
  • Sanofi
  • Sareum Holdings Plc
  • SciTech Development LLC
  • SELLAS Life Sciences Group Inc
  • Shanghai Bioray Laboratory Inc
  • Shanghai GeneChem Co Ltd
  • Shanghai Longyao Biotechnology Inc Ltd
  • Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
  • Shanghai YaKe Biotechnology Inc
  • Shenzhen BinDeBio Ltd
  • Sian Wuhan Medical Technology Co Ltd
  • SpecificiT Pharma Inc
  • Spectrum Pharmaceuticals Inc
  • AIkido Pharma Inc
  • Sun Pharma Advanced Research Company Ltd
  • Sunnycell Therapeutics Ltd
  • SunRock Biopharma SL
  • Syndax Pharmaceuticals Inc
  • SYNIMMUNE GmbH
  • Tacitus Therapeutics Inc
  • Takara Bio Inc
  • Takeda Pharmaceutical Co Ltd
  • TC BioPharm Ltd
  • TCR2 Therapeutics Inc
  • TheraPharm Deutschland GmbH
  • Tianjin Mycure Medical Technology Co Ltd
  • Tolero Pharmaceuticals Inc
  • Trillium Therapeutics Inc
  • Triphase Accelerator Corp
  • UWELL Biopharma Inc
  • VelosBio Inc
  • Vor BioPharma Inc
  • Wugen Inc
  • Wuhan Bio-Raid Biotechnology Co Ltd
  • Xbrane Biopharma AB
  • Xencor Inc
  • Zhejiang Teruisi Pharmaceutical Inc
  • Zhuobo Yong Ji (Shanghai) Biological Pharmaceutical Co Ltd
  • ZIOPHARM Oncology Inc
  • Zovis Pharmaceuticals
Note: Product cover images may vary from those shown
Adroll
adroll